Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | not detected in single-cell data | 0.00 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 15697
Sealed predictions
- RTL10 in dopamine neurons, braak-0.29 (p 0.443) → -0.25 (p 0.514)receipt 15705
Swarm cases
receipt 15705: RTL10 in dopamine neurons, braak
- power
- full sample -0.28 (p 0.258, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.34 (p 0.164, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.123, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.19, sign flips 0; without severely affected donors -0.28 (p 0.258, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.81 (p 5.4e-5, n 18) vs -0.28 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RTL10 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RTL10 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.18 p 0.534 (needs p < 1.5e-4)
Receipts
loading the receipts